Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingre Jiedu Fang No. 2 (QRJDF2) is a Traditional Chinese Medicine (TCM) herbal formula developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is a specific hospital-made preparation (协定方) designed to clear heat and detoxify according to TCM principles. The formula gained significant attention during the COVID-19 pandemic in Shanghai, where it was utilized in clinical settings to treat patients with mild to moderate viral pneumonia. QRJDF2 is composed of several botanical extracts known for their antiviral, anti-inflammatory, and immunomodulatory properties, including *Lonicerae Japonicae Flos* and *Forsythiae Fructus*. Clinical research has focused on its ability to reduce viral load, shorten the duration of symptoms, and prevent the progression of respiratory distress by modulating the host's inflammatory cytokine response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingre Jiedu Fang No. 2.